SCHRODINGER INC (SDGR) competitors & alternatives
Health Care · NASDAQ
SCHRODINGER INC (SDGR)'s top competitors and alternatives — its most similar public companies — include GENERATE BIOMEDICINES INC (GENB), RELAY THERAPEUTICS INC (RLAY), RECURSION PHARMACEUTICALS INC CLAS (RXRX), SIMULATIONS PLUS INC (SLP), Certara, Inc. (CERT), NURIX THERAPEUTICS INC (NRIX), Tempus AI (TEM), OMNIAB INC (OABI), Revvity (RVTY), MONTE ROSA THERAPEUTICS INC (GLUE), RAPPORT THERAPEUTICS INC (RAPP) and ONKURE THERAPEUTICS INC CLASS A (OKUR). These are SCHRODINGER INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top SDGR competitors & alternatives
-
GENERATE BIOMEDICINES INCGENBHealth Care
Generate Biomedicines is a clinical-stage biotechnology company leveraging generative artificial intelligence to design novel, programmable protein…
$13.90 (as of 2026-07-22) · market cap $1.8B
-
RELAY THERAPEUTICS INCRLAYHealth Care
A precision medicine company using computational drug discovery to target protein motion and advance a pipeline of novel small molecule therapeutics.
$19.27 (as of 2026-07-22) · market cap $4.2B
-
RECURSION PHARMACEUTICALS INC CLASRXRXHealth Care
Recursion is a clinical-stage TechBio company using an AI-native operating system and massive biological datasets to industrialize and accelerate the drug…
$2.98 (as of 2026-07-22) · market cap $1.6B
-
SIMULATIONS PLUS INCSLPHealth Care
Simulations Plus provides advanced modeling and simulation software and services to accelerate drug discovery and clinical development for the life sciences…
$18.25 (as of 2026-07-22) · market cap $368M
-
Certara, Inc.CERTHealth Care
Certara utilizes proprietary biosimulation software and expert-led AI to help pharmaceutical companies optimize drug development and increase the probability…
$6.89 (as of 2026-07-22) · market cap $1.1B
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
-
Tempus AITEMHealth Care
Tempus AI leverages genomic sequencing, clinical data aggregation, and machine learning to deliver precision oncology diagnostics and AI-powered treatment…
$46.96 (as of 2026-07-22) · market cap $8.4B
-
OMNIAB INCOABIHealth Care
OmniAb provides a proprietary, AI-enhanced transgenic animal platform that accelerates the discovery of human antibody therapeutics for global pharmaceutical…
$2.11 (as of 2026-07-22) · market cap $300M
-
RevvityRVTYHealth Care
Revvity is a leading health science technology company providing integrated workflows and reagents spanning drug discovery, development, and diagnostic…
$110.54 (as of 2026-07-22) · market cap $12.3B
-
MONTE ROSA THERAPEUTICS INCGLUEHealth Care
Monte Rosa Therapeutics develops molecular glue degraders—a novel class of protein degradation drugs targeting historically undruggable proteins through its…
$23.79 (as of 2026-07-22) · market cap $2.0B
-
RAPPORT THERAPEUTICS INCRAPPHealth Care
Rapport Therapeutics is a clinical-stage biotechnology company using a proprietary precision medicine platform to develop targeted therapies for complex…
$41.33 (as of 2026-07-22) · market cap $2.1B
-
ONKURE THERAPEUTICS INC CLASS AOKURHealth Care
OnKure Therapeutics is a clinical-stage biotech developing precision small molecule drugs that selectively target mutated proteins to treat cancer and vascular…
$4.32 (as of 2026-07-22) · market cap $175M
Not quite? Describe exactly what you want →
Peers are SCHRODINGER INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: SCHRODINGER INC (SDGR).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.